刘清杏;臧洁;任家坤;朱朝晖;
LIU Qing-xing;ZANG Jie;REN Jia-kun;ZHU Zhao-hui;Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College;

• 1:中国医学科学院北京协和医学院北京协和医院核医学科

摘要(Abstract)：

神经内分泌肿瘤(neuroendocrine neoplasm, NEN)是以神经内分泌分化为主要特征的一组不同类型的肿瘤。多数NEN细胞表面有生长抑素受体(somatostatin receptor, SSTR)高表达,为核医学分子影像诊断及多肽-受体介导的放射性核素治疗(peptide receptor radionuclide therapy, PRRT)提供了重要靶点。这一方向近年来已成为国内外的研究热点,且临床转化和应用进展迅速,不断出现新的突破。本文系统介绍靶向SSTR的核医学分子影像和PRRT治疗的现状与进展,以及在NEN诊疗中的主要优势和重要价值,为相关专业临床诊疗决策提供参考。
Neuroendocrine neoplasm(NEN) is a heterogeneous group of tumors characterized by neuroendocrine differentiation. Most of the tumor cells show high-level expression of the somatostatin receptor(SSTR), which provides an important target for molecular imaging and peptide receptor radionuclide therapy(PRRT). This area has become a research hotspot at home and abroad in recent years. In addition, rapid progress and new breakthroughs have been made in clinical translation and application continuously. This article reviewed the new advances in SSTR-targeted nuclear molecular imaging and PRRT, and summarized their main advantages and important values in the diagnosis and treatment of NEN, in hope of giving relevant professional doctors a reference for clinical diagnosis and treatment.

关键词(KeyWords)： 神经内分泌肿瘤;核医学;分子影像;多肽-受体介导的放射性核素治疗
neuroendocrine neoplasm;nuclear medicine;molecular imaging;peptide receptor radionuclide therapy

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(8187071730);; 中国医学科学院重大协同创新项目(2019-I2M-1-001);中国医学科学院临床与转化医学研究基金(2019XK320032)

作者(Authors): 刘清杏;臧洁;任家坤;朱朝晖;
LIU Qing-xing;ZANG Jie;REN Jia-kun;ZHU Zhao-hui;Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College;

参考文献(References)：

• [1] Kim JY,Hong SM,Ro JY,et al.Recent updates on grading and classification of neuroendocrine tumors [J].Ann Diagn Pathol,2017,29:11- 16.
• [2] 陈野野,刘洪生,李单青,等.胸腺神经内分泌肿瘤手术治疗及预后因素[J].协和医学杂志,2016,7:190- 194.
• [3] Theodoropoulou M,Stalla GK.Somatostatin receptors:from signaling to clinical practice [J].Front Neuroendocrinol,2013,34:228- 252.
• [4] Lee ST,Kulkarni HR,Singh A,et al.Theranostics of neuroendocrine tumors [J].Visc Med,2017,33:358- 366.
• [5] Bombardieri E,Maccauro M,De Deckere E,et al.Nuclear medicine imaging of neuroendocrine tumours [J].Ann Oncol,2001,12 Suppl 2:S51-S61.
• [6] O’Toole D,Ducreux M,Bommelaer G,et al.Treatment of carcinoid syndrome:a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy,patient acceptability,and tolerance [J].Cancer,2000,88:770- 776.
• [7] Tian R,Jacobson O,Niu G,et al.Evans blue attachment enhances somatostatin receptor subtype- 2 imaging and radiotherapy [J].Theranostics,2018,8:735- 745.
• [8] Zhang J,Wang H,Jacobson O,et al.Safety,pharmacokinetics and dosimetry of a long-acting radiolabeled somatosta-tin analogue 177Lu-DOTA-EB-TATE in patients with advan-ced metastatic neuroendocrine tumors [J].J Nucl Med,2018,59:1699- 1705.
• [9] Fani M,Braun F,Waser B,et al.Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications [J].J Nucl Med,2012,53:1481- 1489.
• [10] Ginj M,Zhang HW,Waser B,et al.Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors [J].Proc Natl Acad Sci U S A,2006,103:16436- 16441.
• [11] Zhang J,Singh A,Kulkarni HR,et al.From bench to bedside-the Bad Berka experience with first-in-human studies [J].Semin Nucl Med,2019,49:422- 437.
• [12] Werner RA,Weich A,Kircher M,et al.The theranostic promise for neuroendocrine tumors in the late 2010s- where do we stand,where do we go?[J].Theranostics,2018,8:6088- 6100.
• [13] Waldmann CM,Stuparu AD,van Dam RM,et al.The search for an alternative to [(68)Ga]Ga-DOTA-TATE in neuroendocrine tumor theranostics:current state of (18)F-labeled somatostatin analog development [J].Theranostics,2019,9:1336- 1347.
• [14] 谭思婷,尹吉林,王欣璐,等.64Cu标记生长抑素受体显像剂的研究进展[J].中国医学计算机成像杂志,2015,21:398- 401.
• [15] Hope TA,Bergsland EK,Bozkurt MF,et al.Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors [J].J Nucl Med,2018,59:66- 74.
• [16] Imhof A,Brunner P,Marincek N,et al.Response,survival,and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers [J].J Clin Oncol,2011,29:2416- 2423.
• [17] Kwekkeboom DJ,de Herder WW,Kam BL,et al.Treat-ment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate:toxicity,efficacy,and survival[J].J Clin Oncol,2008,26:2124- 2130.
• [18] Muller C,Reber J,Haller S,et al.Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate [J].Eur J Nucl Med Mol I,2014,41:476- 485.
• [19] Hindie E,Zanotti-Fregonara P,Quinto MA,et al.Dose deposits from 90Y,177Lu,111In,and 161Tb in micrometastases of various sizes:implications for radiopharmaceutical therapy [J].J Nucl Med,2016,57:759- 764.
• [20] Pomme S,Marouli M,Suliman G,et al.Measurement of the 225Ac half-life [J].Appl Radiat Isot,2012,70:2608- 2614.
• [21] Sgouros G,Roeske JC,McDevitt MR,et al.MIRD Pamphlet No.22 (abridged):radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy [J].J Nucl Med,2010,51:311- 328.
• [22] Kratochwil C,Giesel FL,Bruchertseifer F,et al.213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation:a first-in-human experience [J].Eur J Nucl Med Mol I,2014,41:2106- 2119.
• [23] Haidar M,Shamseddine A,Panagiotidis E,et al.The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tu-mors:real-world experience from two large neuroendocrine tumor centers[J].Nucl Med Commun,2017,38:170- 177.
• [24] Chen SH,Chang YC,Hwang TL,et al.68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors:A prospective study in Taiwan[J].J Formos Med Assoc,2018,117:480- 487.
• [25] Werner RA,Bundschuh RA,Bundschuh L,et al.Molecular imaging reporting and data systems (MI-RADS):a generalizable framework for targeted radiotracers with theranostic implications [J].Ann Nucl Med,2018,32:512- 522.
• [26] Werner RA,Thackeray JT,Pomper MG,et al.Recent updates on molecular imaging reporting and data systems (MI-RADS) for theranostic radiotracers-navigating pitfalls of SSTR- and PSMA-targeted PET/CT [J].J Clin Med,2019,8:1060.
• [27] Werner RA,Solnes LB,Javadi MS,et al.SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates:a proposed standardization framework [J].J Nucl Med,2018,59:1085- 1091.
• [28] Dieter H,Samer E,Alexander H,et al.Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany:A multi-institutional registry study with prospective follow-up[J].Eur J Cancer,2016,58:41- 51.
• [29] Baum R,Kulkarni H,Singh A,et al.Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms[J].Oncotarget,2018,9:16932- 16950.
• [30] Kunikowska J,Pawlak D,Bak MI,et al.Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location:a 10-year study [J].Ann Nucl Med,2017,31:347- 356.
• [31] Claringbold PG,Brayshaw PA,Price RA,et al.Phase Ⅱ study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours [J].Eur J Nucl Med Mol I,2011,38:302- 311.
• [32] Claringbold PG,Price RA,Turner JH,et al.Phase Ⅰ-Ⅱ study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors[J].Cancer Biother Radiopharm,2012,27:561- 569.
• [33] Kesavan M,Claringbold PG,Turner JH,et al.Hemato-logical toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up[J].Neuroendocrinology,2014,99:108- 117.
• [34] Claringbold PG,Turner JH.Pancreatic neuroendocrine tu-mor control:durable objective response to combination 177Lu-octreotatecapecitabine-temozolomide radiopeptide chemo-therapy[J].Neuroendocrinology,2016,103:432- 439.
• [35] Claringbold PG,Turner JH.NeuroEndocrine Tumor Therapy with Lutetium- 177-octreotate and Everolimus (NETTLE):a phase I study[J].Cancer Biother Radiopharm,2015,30:261- 269.
• [36] McStay MK,Maudgil D,Williams M,et al.Large-volume liver metastases from neuroendocrine tumors:hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy [J].Radiology,2005,237:718- 726.
• [37] Chan DL,Pavlakis N,Schembri GP,et al.Dual somatos-tatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours:proposal for a novel grading scheme with prognostic significance[J].Theranostics,2017,7:1149- 1158.
• [38] Bozkurt MF,Virgolini I,Balogova S,et al.Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA [J].Eur J Nucl Med Mol I,2017,44:1588- 1601.
• [39] Strosberg J,El-Haddad G,Wolin E,et al.Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [J].N Engl J Med,2017,376:125- 135.